Olympus rolls out three EndoClot portfolio products in EMEA region
21 Apr 2023
License out/in
Olympus will distribute EndoClot Adhesive (ECA), EndoClot Polysaccharide Haemostatic Spray (PHS) and EndoClot Submucosal Injection Solution (SIS) in the EMEA region, under an expanded distribution agreement signed in December last year
EndoClot PHS is used to stop bleeding during procedures. (Credit: PRNewswire/Olympus Europa SE & Co. KG)
Olympus has introduced three haemostasis products developed by US-based medical device company EndoClot Plus, in the Europe, Middle East and Africa (EMEA) region.
The products include EndoClot Adhesive (ECA), EndoClot Polysaccharide Haemostatic Spray (PHS) and EndoClot Submucosal Injection Solution (SIS).
In April last year, Olympus signed an agreement with EndoClot Plus to distribute the latter’s products in the US.
In December, the companies expanded their distribution agreement to include the EMEA region.
EndoClot ECA is a single-use medical device that contains Haemostatic Polymer (AHP), a durable haemostatic polymer resistant to acids and bases in the GI tract, to seal the lesions.
It is a durable adhesive, recommended for use at the end of the procedure to stop and control oozing bleeding, prevent re-bleeding and protect the wound from irritation by acids and bases.
EndoClot PHS is a single-use product that contains a powder haemostat intended to be applied directly to the bleeding site using a flexible endoscope to stop bleeding during procedures.
EndoClot SIS is intended for use in gastrointestinal endoscopic procedures.
It supports an optimal submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with an endoscopic knife or snare.
Both EndoClot PHS and EndoClot SIS are developed based on the starch-based EndoClot Absorbable Modified Polymer (AMP) technology.
The EndoClot AMP particles are biocompatible, bioabsorbable, non-pyrogenic, starch derived and contain no animal or human components, which work by absorbing water from the blood.
Olympus said that EndoClot ECA and EndoClot PHS will enable healthcare professionals to apply an advanced powder haemostat using a portable air compressor for stable air pressure.
Olympus GI EndoTherapy EMEA business unit manager Stefanie Kaufung said: “We are excited to expand our global partnership with EndoClot Plus.
“The addition of their solutions to our portfolio allows us to strengthen our commitment to our customers as a full gastrointestinal solution provider for advanced therapeutic procedures.
“Endoscopic resection and associated bleeding management are among Olympus’ core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard of care.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.